Oil slides as US-Iran tensions ease; AstraZeneca beats profit forecasts

Oil prices fell on Monday as tensions between the US and Iran appeared to ease, while AstraZeneca reported better-than-expected profits driven by strong sales of its cancer treatments. The developments came as markets reacted to a mix of geopolitical and corporate news.

The decline in oil prices followed signals that the US and Iran may be moving toward de-escalation after weeks of heightened rhetoric. This affected global energy markets, with benchmark crude prices dropping by more than 2% in early trading. The easing of tensions reduced fears of supply disruptions from the Middle East, a key oil-producing region.

AstraZeneca, the Anglo-Swedish pharmaceutical giant, posted quarterly profits that beat analyst forecasts, thanks largely to its portfolio of cancer drugs. The company reported a 15% rise in revenue for the third quarter, reaching $12.8 billion, with oncology sales up 19%. This matters because AstraZeneca is a major player in the global drug market, and its performance often signals broader trends in the healthcare sector.

The oil price slide comes after weeks of volatility driven by geopolitical risks. Earlier this month, prices had spiked on fears of a broader conflict involving Iran. Meanwhile, AstraZeneca's results follow a series of strong earnings from other drugmakers, underscoring the resilience of the pharmaceutical industry amid economic uncertainty.

Looking ahead, analysts expect oil prices to remain sensitive to any further developments in US-Iran relations. For AstraZeneca, the company maintained its full-year guidance, suggesting confidence in continued growth from its cancer drug pipeline. Investors will watch for any new product approvals or regulatory decisions that could affect the company's outlook.